KCM
NKTR icon

Kennedy Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Kennedy Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,473
Closed -$3.18M – 721
2018
Q3 		$3.18M Buy
3,473
+118
+4% +$101K 0.06% 517
2018
Q2 		$2.46M Sell
3,355
-2,876
-46% -$3.32M 0.05% 575
2018
Q1 		$9.93M Sell
6,231
-12,494
-67% -$16.1M 0.19% 152
2017
Q4 		$16.8M Sell
18,725
-5,592
-23% -$3.31M 0.3% 73
2017
Q3 		$8.75M Buy
+24,317
New +$7.61M 0.16% 208

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kennedy Capital Management's NKTR Position: Q4 2018 in Review

Kennedy Capital Management sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 3,473 shares — an estimated $3.18M sold.

Kennedy Capital Management first reported a position in NKTR in Q3 2017 and held it in 5 quarters. The position peaked at $16.8M in Q4 2017. 343 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Kennedy Capital Management reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Kennedy Capital Management sold 3,473 Nektar Therapeutics shares in Q4 2018, an estimated $3.18M.
  • Kennedy Capital Management first reported a position in Nektar Therapeutics in Q3 2017 and held it in 5 quarters.
  • Kennedy Capital Management's Nektar Therapeutics position peaked at $16.8M in Q4 2017.
  • 343 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Kennedy Capital Management's 13F filing for Q4 2018, filed 12 Feb 2019.